Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (11-20 of 184) with videos related to

Pageof 19
Sort By:
Haematologica|December 4, 2012
Primetime for chemotherapy in acute myeloid leukemiaJan Cools
Haematologica|March 3, 2012
Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemiaJan Cools
Chemistry & Biology|March 29, 2011
JAK3 specific kinase inhibitors: when specificity is not enoughLuk Cox, Jan Cools
Blood Cancer Discovery|October 18, 2021
Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic LeukemiaHeidi Segers, Jan Cools
Haematologica|February 22, 2024
The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemiaKrista Verhoeft, Jan Cools
Hemasphere|November 15, 2019
The First Year of HemaSphere and Many More to ComeAndreas Engert, Jan Cools
Haematologica|February 14, 2007
TV6 and PDGFRB: a license to fuseEls Lierman, Jan Cools
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid MalignanciesInge Lodewijckx, Jan Cools
Journal of Hematology & Oncology|July 26, 2015
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemiaSandrine Degryse, Jan Cools
Haematologica|June 6, 2012
New opportunities and new problems for acute myeloid leukemia treatmentIdoya Lahortiga, Jan Cools
Pageof 19

Showing results (11-20 of 184) with videos related to

Sort By:
Pageof 19
Haematologica|December 4, 2012
Primetime for chemotherapy in acute myeloid leukemiaJan Cools
Haematologica|March 3, 2012
Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemiaJan Cools
Chemistry & Biology|March 29, 2011
JAK3 specific kinase inhibitors: when specificity is not enoughLuk Cox, Jan Cools
Blood Cancer Discovery|October 18, 2021
Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic LeukemiaHeidi Segers, Jan Cools
Haematologica|February 22, 2024
The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemiaKrista Verhoeft, Jan Cools
Hemasphere|November 15, 2019
The First Year of HemaSphere and Many More to ComeAndreas Engert, Jan Cools
Haematologica|February 14, 2007
TV6 and PDGFRB: a license to fuseEls Lierman, Jan Cools
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid MalignanciesInge Lodewijckx, Jan Cools
Journal of Hematology & Oncology|July 26, 2015
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemiaSandrine Degryse, Jan Cools
Haematologica|June 6, 2012
New opportunities and new problems for acute myeloid leukemia treatmentIdoya Lahortiga, Jan Cools
Pageof 19